GSK’s Long-Term Nucala Study in EGPA Nears the Finish Line: What Investors Should Know

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

Study Overview
GlaxoSmithKline (GSK) is running an observational study called “NUCALA® Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term)” to track how its drug Nucala performs in everyday use for patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss syndrome. The aim is to gather real-world data on long-term safety and effectiveness after approval, supporting treatment decisions in a rare and serious disease area.

Intervention/Treatment
The study focuses on Nucala, a prescription injection used to treat EGPA. It is a drug given under the skin, and doctors in normal practice decide the dose and schedule. The intention is to see how patients respond over time and to watch for side effects when the medicine is used outside a strict trial setting.

Study Design
This is an observational study, not a randomized trial. All participants receive Nucala; there is no comparison group or placebo. Researchers follow patients prospectively, meaning they track outcomes going forward from the start of Nucala treatment. There is no masking or blinding, as both doctors and patients know they are using Nucala. The main purpose is to monitor use in real life rather than to test a new experimental option.

Study Timeline
The study was first submitted in June 2018, shortly after Nucala gained approval for EGPA, reflecting an early push to collect post-approval evidence. Each patient can be observed for up to 96 weeks, with an additional 48 weeks of follow-up in some cases, giving roughly three years of data from approval to planned end of the investigation. According to the latest update posted on January 28, 2026, the study is listed as completed, which means core data collection has finished, but top-line results have not yet been submitted to the registry.

Market Implications
For investors, this update signals that GSK is close to having long-term, real-world evidence for Nucala in EGPA, a rare disease with limited treatment options. Strong safety and durability data could reinforce Nucala’s positioning in severe inflammatory and eosinophilic conditions, supporting steady revenue from specialty respiratory and immunology products. As competitors in biologic asthma and eosinophilic disease, such as AstraZeneca and others, look to expand labels and real-world claims, GSK’s ability to show long-term performance in EGPA may help defend its share and sustain pricing power. Investor sentiment will depend on whether forthcoming data confirm the risk-benefit profile seen in earlier controlled trials and expand confidence in chronic use. While immediate stock reactions may be modest until results are public, the completion of this long-term study reduces regulatory uncertainty and may be a quiet positive for GSK’s medium-term outlook in specialty medicines.

The study is now completed and recently updated, with more detailed information available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.